Skip to content

Study · Randomized controlled trial · n = 55 · 2013

1 result

An interaction between oxytocin and a genetic variation of the oxytocin receptor modulates amygdala activity toward direct gaze: evidence from a pharmacological imaging genetics study.

Montag C, Sauer C, Reuter M, Kirsch P

European archives of psychiatry and clinical neuroscience27 Sept 2013Cited by 26 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy men given intranasal oxytocin, carriers of the heterozygous CT variant of OXTR rs401015 showed higher right amygdala activity for direct versus averted gaze than the TT group.

    In plain wordsIn healthy men given oxytocin, men with the CT gene variant showed more amygdala activity during direct gaze than men with the TT variant.

    Peptide
    Oxytocin
    Outcome
    Not applicableRight amygdala activity, direct > averted gaze, by OXTR rs401015 genotype
    Study

    n = 55

    Comparator
    TT genotype
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The main result revealed that a genetic variation of the OXTR gene (rs401015) modulated the right amygdala activity for the fMRI contrast "direct > averted gaze" under the influence of the neuropeptide oxytocin. Here, carriers of the heterozygous CT variant showed higher activity compared to the TT group.
    1 context sentence
    Summary · context
    N = 55 healthy males were invited to an oxytocin challenge study administered while watching direct vs. averted gaze pictures in an fMRI setting.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.